Home > News > Cognitive and Behavioural Predictors of Alzheimer’s Disease Progression
Alzheimer's Disease & Dementia
Read Time: 2 mins

Cognitive and Behavioural Predictors of Alzheimer’s Disease Progression

Published Online: May 15th 2012 European Neurological Review, 2012;7(2):103-6 DOI: http://doi.org/10.17925/ENR.2012.07.02.103
Authors: John M Starr, Tom C Russ, Sarah McGrory
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Alzheimer’s disease (AD) can be thought of as divided into pre- and post-diagnostic phases. There is evidence that cognitive and behavioural traits influence the risk of AD diagnosis. Following diagnosis, it may be difficult to tangle the causal direction between cognitive and behavioural measures as predictors or manifestations of AD progress, though people with higher lifetime cognitive trait scores appear to be protected somewhat against worsening cognitive scores and behavioural changes. The pre-diagnostic phase can be considered as a state where AD neuropathology is progressing without manifestations of this and a prodromal phase where, typically, episodic memory is impaired. Far fewer data exist that inform about the effects of cognitive or behavioural predictors during this phase, though those from large brain tissue bank collaborations indicate that education, a correlate of cognitive function, does not influence the extent of neuropathology.

Keywords

Alzheimer’s disease, dementia, disease progression, Down syndrome, cognition, neuropsychiatric symptoms, activities of daily living, depression, item response theory

Article:

Alzheimer’s disease (AD) is the commonest cause of dementia. It is characterised by the presence of senile amyloid plaques and neurofibrillary tangles and clinical characteristics consistent with gradual deterioration in memory function of at least six months duration together with other neuropsychological deficits, most typically aphasia, agnosia, apraxia and disturbance in executive function. Although, strictly speaking, AD cannot be diagnosed in the absence of clinical features, it is generally accepted that there is a preclinical phase that can be present for several years during which the underlying pathological features are progressing. Sometimes a further prodromal phase is defined, manifested as amnestic mild cognitive impairment (aMCI)1. aMCI is a state where memory function is impaired at least 1.5 standard deviations below the mean, but where other cognitive domains remain relatively unaffected and where there is none or only minimal impairment of social function and activities of daily living (ADL). Once a person has entered the clinical phase of AD, non-memory cognitive domains are progressively involved together with deterioration in ADL. Figure 1 demonstrates this schema of AD progression.

A Clinical Dementia Rating (CDR) scale2 has been devised to reflect this progression in both cognition and ADL. The CDR rating can take the value of zero for absence of dementia, 0.5 very mild, 1.0 mild, 2.0 moderate and 3.0 severe dementia.

In addition, progression to clinical AD may also be accompanied by behavioural changes. Such changes may occur at any phase and insome types of AD, such as that seen in adults with Down syndrome (DS), typically occurs at an early stage and may be an initial symptom.3 Moreover, some psychological or behavioural symptoms may pre-date clinical AD by several years and thus be considered as predictors of progression.

In this review, we will consider cognitive and behavioural predictors relevant to each stage of AD progression as represented in Figure 1.

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:
Disclosure

The authors have no conflicts of interest to declare.

Correspondence

John M Starr, Alzheimer Scotland Dementia Research Centre, 7 George Square, Edinburgh EH8 9JZ, UK. E: jstarr@staffmail.ed.ac.uk

Received

2012-05-27T00:00:00

References

  1. Petersen RC, Mild cognitive impairment as a diagnostic entity, J Intern Med, 2004;256:183–94.
  2. Morris JC, The Clinical Dementia Rating (CDR): current version and scoring rules, Neurology, 1993;43:2412–4.
  3. Roizen NJ, Patterson D, Down’s syndrome, Lancet, 2003;361:1281–9.
  4. Brayne C, Ince PG, Keage HAD, et al., Education, the brain and dementia: neuroprotection or compensation?, Brain, 2010;133:2210–6.
  5. Cummings JL, Cognitive and behavioral heterogeneity in Alzheimer’s disease: seeking the neurobiological basis, Neurobiol Aging, 2000;21:845–61.
  6. Deary IJ, Whalley LJ, Lemmon H, et al., The stability of individual differences in mental ability from childhood to old age: Follow-up of the 1932 Scottish Mental Survey, Intelligence, 2000;28:49–55.
  7. Crawford JR, Deary IJ, Starr J, Whalley LJ, The NART as an index of prior intellectual functioning: a retrospective validity study covering a 66-year interval, Psychol Med, 2001;31:451–8.
  8. Starr JM, Whalley LJ, Inch S, Shering PA, The quantification of the relative effects of age and NART‐predicted IQ on cognitive function in healthy old people, Int J Geriatr Psychiatry, 1992;7:153–7.
  9. Deary IJ, Starr JM, MacLennan W, Fluid intelligence, memory and blood pressure in cognitive aging, Pers Indiv Differ, 1998;25:605–19.
  10. Whalley LJ, Sharma S, Fox HC, et al., Anticholinergic drugs in late life: adverse effects on cognition but not on progress to dementia, J Alzheimers Dis, 2012;30:253–61.
  11. Reid LM, MacLullich AMJ, Subjective memory complaints and cognitive impairment in older people, Dement Geriatr Cogn Dis, 2006;22:471–85.
  12. Braak H, Braak E, Frequency of stages of Alzheimer-related lesions in different age categories, Neurobiol Aging, 1997;18:351–7.
  13. Byers AL, Yaffe K, Depression and risk of developing dementia, Nat Rev Neurol, 2011;7:323–31.
  14. Barnes DE, Yaffe K, McCormick M, Schaefer C, et al., Midlife versus late-life depression and risk of dementia: Differential effects for vascular dementia and Alzheimer’s disease, Alzheimer Dement, 2010;6:S109.
  15. Gatz JL, Tyas SL, John PS, Montgomery P, Do depressive symptoms predict Alzheimer’s disease and dementia?, J Gerontol A Biol, 2005;60:744–7.
  16. Byers AL, Covinsky KE, Barnes DE, Yaffe K, Dysthymia and depression increase risk of dementia and mortality among older veterans, Am J Geriatr Psychiat, 2011 May 18 [Epub ahead of print].
  17. Russ TC, Hamer M, Stamatakis E, et al., Psychological distress as a risk factor for dementia death, Arch Intern Med, 2011;171:1858–9.
  18. Brown ES, Varghese FP, McEwen BS, Association of depression with medical illness: does cortisol play a role?, Biol Psychiatry, 2004;55:1–9.
  19. Alexopoulos GS, Meyers BS, Young RC, et al., ‘Vascular depression’ hypothesis, Arch Gen Psychiatr, 1997;54:915–22.
  20. Baldwin RC, Is vascular depression a distinct sub-type of depressive disorder? A review of causal evidence, Int J Geriatr Psychiatry, 2005;20:1–11.
  21. Whitmer RA, Sidney S, Selby J, et al., Midlife cardiovascular risk factors and risk of dementia in late life, Neurology, 2005;64:277–81.
  22. Parra MA, Abrahams S, Logie RH, et al., Visual short-term memory binding deficits in familial Alzheimer’s disease, Brain, 2010;133:2702–13.
  23. Whalley L, Starr J, Athawes R, et al., Childhood mental ability and dementia, Neurology, 2000;55:1455–9.
  24. McGurn B, Deary IJ, Starr JM, Childhood cognitive ability and risk of late-onset Alzheimer and vascular dementia, Neurology, 2008;71:1051–6.
  25. Whalley LJ, Deary IJ, Appleton CL, Starr JM, Cognitive reserve and the neurobiology of cognitive aging, Ageing Res Rev, 2004;3:369–82.
  26. Deary IJ, Whiteman MC, Pattie A, et al., The APOE epsilon 4 allele and cognitive change from age 11 to age 80, Nature, 2002;418:932.
  27. Hamilton G, Harris SE, Davies G, et al., Alzheimer’s disease genes are associated with measures of cognitive ageing in the lothian birth cohorts of 1921 and 1936, Int J Alzheimers Dis, 2011 Jun 12 [Epub ahead of print].
  28. Teng E, Lu PH, Cummings JL, Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer’s disease, Dement Geriatr Cogn Disord, 2007;24:253–9.
  29. Hsiung GYR, Alipour S, Jacova C, et al., Transition from cognitively impaired not demented to Alzheimer’s disease: an analysis of changes in functional abilities in a dementia clinic cohort, Dement Geriatr Cogn Disord, 2008;25:483–90.
  30. Amieva H, Le Goff M, Millet X, et al., Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms, Ann Neurol, 2008;64:492–8.
  31. McGurn B, Starr J, Topfer J, et al., Pronunciation of irregular words is preserved in dementia, validating premorbid IQ estimation, Neurology, 2004;62:1184–6.
  32. Starr JM, Lonie J, The influence of pre-morbid IQ on Mini-Mental State Examination score at time of dementia presentation, Int J Geriatr Psychiatry, 2007;22:382–4.
  33. Starr J, Lonie J, Estimated pre-morbid IQ effects on cognitive and functional outcomes in Alzheimer disease: a longitudinal study in a treated cohort, BMC Psychiatry, 2008;8:27.
  34. McHorney CA, Haley SM, Ware JE, Evaluation of the MOS SF-36 physical functioning scale (PF-40): II. Comparison of relative precision using Likert and Rasch scoring methods, J Clin Epidemiol, 1997;50:451–61.
  35. Morales LS, Flowers C, Gutierrez P, et al., Item and scale differential functioning of the Mini-Mental State Exam assessed using the differential item and test functioning (DFIT) framework, Med Care, 2006;44:S143.
  36. Schultz-Larsen K, Kreiner S, Lomholt RK, Mini-Mental Status Examination: mixed Rasch model item analysis derived two different cognitive dimensions of the MMSE, J Clin Epidemiol, 2007;60:268–79.
  37. Galasko D, An integrated approach to the management of Alzheimer’s disease: assessing cognition, function and behaviour, Eur J Neurol, 1998;5:S9–S17.
  38. Njegovan V, Man-Son-Hing M, Mitchell SL, Molnar FJ, The hierarchy of functional loss associated with cognitive decline in older persons, J Gerontol A Biol, 2001;56:M638–M43.
  39. Daltroy LH, Logigian M, Iversen MD, Lian MH, Does musculoskeletal function deteriorate in a predictable sequence in the elderly?, Arthritis Rheum, 1992;5:146–50.
  40. Kovar MG, Powell Lawton M, Functional disability: Activities and instrumental activities of daily living, Annual Review of Gerontology and Geriatrics, 1994;14:57–75.
  41. Norström T, Thorslund M, The structure of IADL and ADL measures: some findings from a Swedish study, Age Ageing, 1991;20:23–8.
  42. Ligtvoet R, van der Ark LA, te Marvelde JM, Sijtsma K, Investigating an invariant item ordering for polytomously scored items, Educ Psychol Meas, 2010;70:578–95.
  43. Fieo R, Watson R, Deary IJ, Starr JM, A revised activities of daily living/instrumental activities of daily living instrument increases interpretive power: theoretical application for functional tasks exercise, Gerontology, 2010;56:483–90.
  44. Fieo RA, Austin EJ, Starr JM, Deary IJ, Calibrating ADL-IADL scales to improve measurement accuracy and to extend the disability construct into the preclinical range: a systematic review, BMC Geriatr, 2011;11:42.
  45. Gauthier S, Gélinas I, Gauthier L, Functional disability in Alzheimer’s disease, Int Psychogeriatr, 1997;9:163–5.
  46. Nygård L, Instrumental activities of daily living: a stepping-stone towards Alzheimer’s disease diagnosis in subjects with mild cognitive impairment?, Acta Neurol Scand, 2003;107:42–6.
  47. Mason SE, McShane R, Ritchie CW, Diagnostic tests for Alzheimer’s disease: rationale, methodology, and challenges, Int J Alzheimer Dis, 2010 Aug 8 [Epub ahead of print].
  48. Ritchie C, Masters CL, Mason SE, et al., Plasma and CSF Abeta for the longitudinal prediction of Alzheimer’s disease dementia and other dementias in people with cognitive decline but no dementia [Protocol], Cochrane DB Syst Rev, 2011;1:CD008782.
  49. Filippini G, Casazza G, Bellatorre AG, et al., The role of MRI in the early diagnosis of Alzheimer’s disease or other dementias in persons with mild cognitive impairment (MCI) [Protocol], Cochrane DB Syst Rev, 2012;2:CD009628.

Further Resources

Share this Article
Related Content In Alzheimer's Disease & Dementia
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72